Article Dans Une Revue Journal of Hypertension Année : 2024

Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension

Résumé

Objective: Ibrutinib has been the first Bruton tyrosine kinase inhibitor (BTKi) authorized for the treatment of B-cell lymphoproliferative disorders (B-LPDs). Numerous publications have confirmed the efficacy of this orally administrated drug in chemo-free regimens for B-LPDs. They also reported several adverse events (AE) associated with ibrutinib treatment. Whether these AEs depended on ibrutinib exposure has however been seldom explored.

Methods: In the study reported here, the incidence of AE was recorded in 92 patients with B-LPD (mostly chronic lymphocytic leukemia n ¼ 79) for whom ibrutinib alone was proposed as fist line therapy. Moreover, a pharmacokinetics (PK) exploration was planned over one day after 1 month treatment. PK assays included drug and metabolite (DHD-ibrutinib) mean/median and maximal plasmatic concentrations as well as areas under the curve (AUE) data.

Results: This PK evaluation was analyzed regarding AEs recorded over the first year of therapy, which were similar as in published reports. PK data disclosed a significant impact of ibrutinib exposure on infections but mostly on the occurrence of hypertension. The latter was mostly related to dihydrodiol-ibrutinib (DHD-ibrutinib) exposure.

Conclusions: These data suggest that a DHD-ibrutinib assay after one month of treatment could be interesting to consider a lower dosage for patients above maximal concentration thresholds for the drug, its metabolite or the sum of both. Whether this can be applied to newer BTKi remains to be explored but it could be important for patients to whom ibrutinib is proposed.

Fichier principal
Vignette du fichier
JH-D-23-00964.pdf (413.01 Ko) Télécharger le fichier
Origine Publication financée par une institution
licence

Dates et versions

inserm-04906955 , version 1 (22-01-2025)

Licence

Identifiants

Citer

Loïc Ysebaert, Caroline Protin, Lucie Obéric, Guillaume Beziat, Sandra de Barros, et al.. Ibrutinib pharmacokinetics in B-lymphoproliferative disorders discloses exposure-related incidence of hypertension. Journal of Hypertension, 2024, Online ahead of print. ⟨10.1097/hjh.0000000000003937⟩. ⟨inserm-04906955⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More